-DOCSTART- -X- O
Peste -X- _ O
des -X- _ O
petits -X- _ O
ruminants -X- _ O
( -X- _ O
PPR -X- _ O
) -X- _ O
is -X- _ O
an -X- _ O
acute -X- _ O
, -X- _ O
febrile -X- _ O
, -X- _ O
viral -X- _ O
disease -X- _ O
of -X- _ O
small -X- _ O
ruminants -X- _ O
that -X- _ O
has -X- _ O
a -X- _ O
significant -X- _ O
economic -X- _ O
impact. -X- _ O
For -X- _ O
many -X- _ O
viral -X- _ O
diseases -X- _ O
, -X- _ O
vaccination -X- _ O
with -X- _ O
virus-like -X- _ O
particles -X- _ O
( -X- _ O
VLPs -X- _ O
) -X- _ O
has -X- _ O
shown -X- _ O
considerable -X- _ O
promise -X- _ O
as -X- _ O
a -X- _ O
prophylactic -X- _ O
approach -X- _ O
; -X- _ O
however -X- _ O
, -X- _ O
the -X- _ O
processes -X- _ O
of -X- _ O
assembly -X- _ O
and -X- _ O
release -X- _ O
of -X- _ O
peste -X- _ B-Intervention
des -X- _ I-Intervention
petits -X- _ I-Intervention
ruminants -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
PPRV -X- _ I-Intervention
) -X- _ I-Intervention
VLPs -X- _ O
are -X- _ O
not -X- _ O
well -X- _ O
characterized -X- _ O
, -X- _ O
and -X- _ O
their -X- _ O
immunogenicity -X- _ O
in -X- _ O
the -X- _ O
host -X- _ O
is -X- _ O
unknown. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
VLPs -X- _ B-Intervention
of -X- _ I-Intervention
PPRV -X- _ I-Intervention
were -X- _ O
generated -X- _ O
in -X- _ O
a -X- _ O
baculovirus -X- _ O
system -X- _ O
through -X- _ O
simultaneous -X- _ O
expression -X- _ O
of -X- _ O
PPRV -X- _ O
matrix -X- _ O
( -X- _ O
M -X- _ O
) -X- _ O
protein -X- _ O
and -X- _ O
hemaglutin -X- _ O
in -X- _ O
( -X- _ O
H -X- _ O
) -X- _ O
or -X- _ O
fusion -X- _ O
( -X- _ O
F -X- _ O
) -X- _ O
protein. -X- _ O
The -X- _ O
released -X- _ B-Outcome
VLPs -X- _ I-Outcome
showed -X- _ I-Outcome
morphology -X- _ I-Outcome
similar -X- _ I-Outcome
to -X- _ I-Outcome
that -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
native -X- _ I-Outcome
virus -X- _ I-Outcome
particles. -X- _ I-Outcome
Subcutaneous -X- _ I-Outcome
injection -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
VLPs -X- _ I-Outcome
( -X- _ I-Outcome
PPRV-H -X- _ I-Outcome
, -X- _ I-Outcome
PPRV-F -X- _ I-Outcome
) -X- _ I-Outcome
into -X- _ I-Outcome
mice -X- _ I-Outcome
and -X- _ I-Outcome
goats -X- _ I-Outcome
elicited -X- _ I-Outcome
PPRV-specific -X- _ I-Outcome
IgG -X- _ I-Outcome
production -X- _ I-Outcome
, -X- _ I-Outcome
increased -X- _ I-Outcome
the -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
virus -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
promoted -X- _ I-Outcome
lymphocyte -X- _ I-Outcome
proliferation. -X- _ I-Outcome
Without -X- _ I-Outcome
adjuvants -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
PPRV-H -X- _ I-Outcome
VLPs -X- _ I-Outcome
was -X- _ I-Outcome
comparable -X- _ I-Outcome
to -X- _ I-Outcome
that -X- _ I-Outcome
obtained -X- _ I-Outcome
using -X- _ I-Outcome
equivalent -X- _ I-Outcome
amounts -X- _ I-Outcome
of -X- _ I-Outcome
PPRV -X- _ I-Outcome
vaccine. -X- _ I-Outcome
Thus -X- _ O
, -X- _ O
our -X- _ O
results -X- _ O
demonstrated -X- _ O
that -X- _ O
VLPs -X- _ O
containing -X- _ O
PPRV -X- _ O
M -X- _ O
protein -X- _ O
and -X- _ O
H -X- _ O
or -X- _ O
F -X- _ O
protein -X- _ O
are -X- _ O
potential -X- _ O
“differentiating -X- _ O
infected -X- _ O
from -X- _ O
vaccinated -X- _ O
animals” -X- _ O
( -X- _ O
DIVA -X- _ O
) -X- _ O
vaccine -X- _ O
candidates -X- _ O
for -X- _ O
the -X- _ O
surveillance -X- _ O
and -X- _ O
eradication -X- _ O
of -X- _ O
PPR -X- _ O
. -X- _ O

